1 Krakauer T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB. Current Drug Targets-Inflammation & Allergy. 2004; 3:3. 317–324.

2 Tseng CK, Lin CK, Chang HW, Wu YH, Yen FL, Chang FR, et al. Aqueous extract of Gracilaria tenuistipitata suppresses LPS-induced NF-κB and MAPK activation in RAW 264.7 and rat peritoneal macrophages and exerts hepatoprotective effects on carbon tetrachloride-treated rat. PloS one. 2014; 9:1. e86557

3 Kofler S, Nickel T, Michael W. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clinical science. 2005; 108:3. 205–213.

4 Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nature reviews immunology. 2008; 8:12. 958–969.

5 Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutation Research/Reviews in Mutation Research. 2008; 659:1. 15–30.

6 Thompson K, Maltby J, Fallowfield J, McAulay M, Millward-Sadler H, Sheron N. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology. 1998; 28:6. 1597–1606.

7 Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992; 103:1. 264–274.

8 Ghazwani M, Zhang Y, Gao X, Fan J, Li J, Li S. Anti-fibrotic effect of thymoquinone on hepatic stellate cells. Phytomedicine. 2014; 21:3. 254–260.

9 Yan HJ, Kwon SY, Kim KS, Jeong HS, Kim Y, Chung WS, et al. Anti-fibrotic effects of Kyungheechunggan-tang on activated hepatic stellate cells and rat liver. Molecular & Cellular Toxicology. 2014; 10:4. 411–421.

10 Barbero-Becerra VJ, Giraudi PJ, Chavez-Tapia NC, Uribe M, Tiribelli C, Rosso N. The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicology in Vitro. 2015; 29:7. 1753–1758.

11 Zhang DQ, Sun P, Jin Q, Li X, Zhang Y, Zhang YJ, et al. Resveratrol Regulates Activated Hepatic Stellate Cells by Modulating NF-κB and the PI3K/Akt Signaling Pathway. Journal of food science. 2016; 81:1. 240–245.

12 Benyon R, Iredale J. Is liver fibrosis reversible? Gut. 2000; 46:4. 443–446.

13 Dufour JF, DeLellis R, Kaplan MM. Reversibility of hepatic fibrosis in autoimmune hepatitis. Annals of internal medicine. 1997; 127:11. 981–985.

14 Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy? Hepatology. 2006; 43:S1. S82–S88.

15 Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Seminars in liver disease. 2001; 21:3. 437–452.

16 Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Critical Reviews™in Therapeutic Drug Carrier Systems. 2007; 24:2. 93–146.

17 Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transplantation. 2003; 9:4. 331–338.

18 Kiemer AK, Muller C, Vollmar AM. Inhibition of LPS-induced nitric oxide and TNF-α production by α-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunology and cell biology. 2002; 80:6. 550–557.

19 Brown KE, Broadhurst KA, Mathahs MM, Brunt EM, Schmidt WN. Expression of HSP47, a collagen-specific chaperone, in normal and diseased human liver. Laboratory investigation. 2005; 85:6. 789–797.

20 Arthur MJ. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2000; 279:2. G245–G249.

21 Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chemico-biological interactions. 2011; 193:3. 225–231.

22 Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition implications for reversibility of liver fibrosis. Journal of Biological Chemistry. 2002; 277:13. 11069–11076.

23 Fowell AJ, Collins JE, Duncombe DR, Pickering JA, Rosenberg WM, Benyon RC. Silencing tissue inhibitors of metalloproteinases (TIMPs) with short interfering RNA reveals a role for TIMP-1 in hepatic stellate cell proliferation. Biochemical and biophysical research communications. 2011; 407:2. 277–282.

24 Han CW, Lee JH. Effects of KHchunggan-tang on the nonalcoholic fatty liver disease in palmitate-induced cellular model. The Journal of Korean Medicine. 2010; 32:1. 109–120.

25 Hong SH, Seo SH, Lee JH, Choi BT. The aqueous extract from Artemisia capillaris Thunb. inhibits lipopolysaccharide-induced inflammatory response through preventing NF-κB activation in human hepatoma cell line and rat liver. International journal of molecular medicine. 2004; 13:5. 717–720.

26 Han JM, Kim HG, Choi MK, Lee JS, Lee JS, Wang JH, et al. Artemisia capillaris extract protects against bile duct ligation-induced liver fibrosis in rats. Experimental and Toxicologic Pathology. 2013; 65:6. 837–844.

27 Hong X, Tang H, Wu L, Li L. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease. Journal of Pharmacy and Pharmacology. 2006; 58:10. 1391–1398.

28 Dong J, Shao W, Yan P, Cai X, Fang L, Zhao X, et al. Curcumolide, a unique sesquiterpenoid with anti-inflammatory properties from Curcuma wenyujin. Bioorganic & medicinal chemistry letters. 2015; 25:2. 198–202.

29 Kao ES, Wang CJ, Lin WL, Yin YF, Wang CP, Tseng TH. Anti-inflammatory potential of flavonoid contents from dried fruit of Crataegus pinnatifida in vitro and in vivo. Journal of agricultural and food chemistry. 2005; 53:2. 430–436.

30 Ahn M, Park JS, Chae S, Kim S, Moon C, Hyun JW, et al. Hepatoprotective effects of Lycium chinense Miller fruit and its constituent betaine in CCl 4-induced hepatic damage in rats. Acta histochemica. 2014; 116:6. 1104–1112.

31 Kim HP, Lee EJ, Kim YC, Kim J, Kim HK, Park JH, et al. Zeaxanthin dipalmitate from Lycium chinense fruit reduces experimentally induced hepatic fibrosis in rats. Biological and Pharmaceutical Bulletin. 2002; 25:3. 390–392.

32 Ceccarelli S, Panera N, Mina M, Gnani D, De Stefanis C, Crudele A, et al. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget. 2015; 6:39. 41434–41452.

33 Tsukamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: a review. Seminars in liver disease. 1990; 10:1. 56–65.

34 Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y. Current status of herbal medicines in chronic liver disease therapy: the biological effects, molecular targets and future prospects. International journal of molecular sciences. 2015; 16:12. 28705–28745.

35 Lee HJ, Zerin T, Kim YH, Lee BE, Song HY. Immunomodulation potential of Artemisia capillaris extract in rat splenocytes. International Journal of Phytomedicine. 2013; 5:3. 356–361.

36 Han CW, Kwun MJ, Kim KH, Choi JY, Oh SR, Ahn KS, et al. Ethanol extract of Alismatis Rhizoma reduces acute lung inflammation by suppressing NF-κB and activating Nrf2. Journal of Ethnopharmacology. 2013; 146:1. 402–410.

37 Robert S, Gicquel T, Bodin A, Lagente V, Boichot E. Characterization of the MMP/TIMP imbalance and collagen production induced by IL-1β or TNF- α release from human hepatic stellate cells. PloS one. 2016; 11:4. e0153118

38 Choi I, Kang HS, Yang Y, Pyun KH. IL-6 induces hepatic inflammation and collagen synthesis in vivo. Clinical & Experimental Immunology. 1994; 95:3. 530–535.

39 Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, et al. Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice. Gut. 2006; 55:3. 415–424.

40 Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJ, Iredale JP, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver International. 2004; 24:5. 492–501.

41 Bataller R, Brenner DA. Liver fibrosis. Journal of clinical investigation. 2005; 115:2. 209–218.